US Patent

US11738120 — Synthesis of taurolidine, purity profiles and polymorphs

Composition of Matter · Assigned to Cormedix Inc · Expires 2042-04-15 · 16y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

Improved methods for synthesizing taurolidine, improved compositions or formulations comprising taurolidine and methods for reducing an amount of impurities in taurolidine are provided herein, among other things. The taurolidine may be substantially free of impurities. The taurol…

USPTO Abstract

Improved methods for synthesizing taurolidine, improved compositions or formulations comprising taurolidine and methods for reducing an amount of impurities in taurolidine are provided herein, among other things. The taurolidine may be substantially free of impurities. The taurolidine may be a polymorph, for example, Polymorph A or Polymorph B. The composition or formulation may comprise Low-Molecular-Weight (LMW) Heparin.

Drugs covered by this patent

Patent Metadata

Patent number
US11738120
Jurisdiction
US
Classification
Composition of Matter
Expires
2042-04-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Cormedix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.